Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1year observational study

Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1year... Background Intravenous (IV) iron preparations bypass the difficulties (malabsorption and side effects) associated with oral iron for the treatment of iron deficiency anaemia (IDA). Ferric carboxymaltose (FCM) can be administered as a single infusion over short periods of time but is more expensive than iron sucrose (IS) when the patients are hospitalized. Objectives To evaluate the appropriateness of FCM prescriptions and to establish the economic impact of this management (including disease coding) compared to the use of IV IS. Setting This study was conducted for inpatients in all departments (orthopaedic department, gastroenterology department and two units of the internal medicine department) where FCM was widely prescribed. Method We retrospectively identified 224 patients, diagnosed with IDA using laboratory parameters and/or disease coding, who received FCM between January and December 2014. Main outcome measure The primary outcome was the rate of appropriateness of FCM prescriptions and the financial impact compared to IV IS. Results 89 Patients were included. The total additional cost for an inappropriate prescription of IV FCM (68% of cases) was of 6053 €. The total incremental cost of unsuitable disease coding was estimated at 31,688 €. Indications for IV FCM were categorized: intestinal bleeding (31%), malabsorption (17%), intolerance (9%) and refractory to oral iron (7%). The majority of patients (62%) received 1000 mg of FCM per week. The average length of hospital stay was of 10 days. Conclusion The prescription of IV iron was appropriate in most cases but did not necessarily require FCM. The use of IV IS, in many cases, could present a cost-saving option for inpatients with IDA. The lack of an IDA coding generated incremental costs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Clinical Pharmacy Springer Journals

Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1year observational study

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/financial-impact-of-intravenous-iron-treatments-on-the-management-of-qEZ2BERoDV
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Pharmacy
ISSN
2210-7703
eISSN
2210-7711
DOI
10.1007/s11096-018-0611-2
pmid
29520555
Publisher site
See Article on Publisher Site

Abstract

Background Intravenous (IV) iron preparations bypass the difficulties (malabsorption and side effects) associated with oral iron for the treatment of iron deficiency anaemia (IDA). Ferric carboxymaltose (FCM) can be administered as a single infusion over short periods of time but is more expensive than iron sucrose (IS) when the patients are hospitalized. Objectives To evaluate the appropriateness of FCM prescriptions and to establish the economic impact of this management (including disease coding) compared to the use of IV IS. Setting This study was conducted for inpatients in all departments (orthopaedic department, gastroenterology department and two units of the internal medicine department) where FCM was widely prescribed. Method We retrospectively identified 224 patients, diagnosed with IDA using laboratory parameters and/or disease coding, who received FCM between January and December 2014. Main outcome measure The primary outcome was the rate of appropriateness of FCM prescriptions and the financial impact compared to IV IS. Results 89 Patients were included. The total additional cost for an inappropriate prescription of IV FCM (68% of cases) was of 6053 €. The total incremental cost of unsuitable disease coding was estimated at 31,688 €. Indications for IV FCM were categorized: intestinal bleeding (31%), malabsorption (17%), intolerance (9%) and refractory to oral iron (7%). The majority of patients (62%) received 1000 mg of FCM per week. The average length of hospital stay was of 10 days. Conclusion The prescription of IV iron was appropriate in most cases but did not necessarily require FCM. The use of IV IS, in many cases, could present a cost-saving option for inpatients with IDA. The lack of an IDA coding generated incremental costs.

Journal

International Journal of Clinical Pharmacy – Springer Journals

Published: Mar 8, 2018

References

  • Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials
    Rognoni, C; Venturini, S; Meregaglia, M; Marmifero, M; Tarricone, R
  • Iron deficiency anemia: evaluation and management
    Short, MW; Domagalski, JE
  • Strategies for iron supplementation: oral versus intravenous
    Macdougall, IC
  • Iron deficiency: a concise review
    Umbreit, J
  • Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency
    Calvet, X; Angel, M; Dosal, A; Moreno, L; Lo’pez, M; Figuerola, A
  • Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
    Fragoulakis, V; Kourlaba, G; Goumenos, D; Konstantoulakis, M; Maniadakis, N
  • European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases
    Dignass, AU; Gasche, C; Bettenworth, D; Birgegård, G; Danese, S; Gisbert, JP
  • Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology
    Kozek-Langenecker, SA; Afshari, A; Albaladejo, P; Santullano, CAA; Robertis, E; Filipescu, DC
  • Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
    Locatelli, F; Bárány, P; Covic, A; Francisco, A; Vecchio, L; Goldsmith, D
  • Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies
    Henry, DH
  • British society of gastroenterology. Guidelines for the management of iron deficiency anaemia
    Goddard, AF; James, MW; McIntyre, AS; Scott, BB
  • The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective
    Bager, P; Dahlerup, JF
  • Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia
    Calvet, X; Gené, E; ÀngelRuíz, M; Figuerola, A; Villoria, A; Cucala, M
  • Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study
    Muñoz, M; Gómez-Ramírez, S; Martín-Montañez, E; Naveira, E; Seara, J; Pavía, J
  • Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data
    Moore, RA; Gaskell, H; Rose, P; Allan, J
  • Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
    Bhandari, S
  • Review of medical discharge summaries and medical documentation in a metropolitan hospital: impact on diagnostic-related groups and weighted inlier equivalent separation
    Chin, N; Perera, P; Roberts, A; Nagappan, R